Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$449.58M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.60 | 3.59%
Avg Daily Range (30 D):	$0.32 | 3.33%
Avg Daily Range (90 D):	$0.31 | 3.37%

Institutional Daily Volume
Avg Daily Volume:	.46M
Avg Daily Volume (30 D):	.56M
Avg Daily Volume (90 D):	.62M

Trade Size
Avg Trade Size (Sh.):	75
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	1,216
Avg Institutional Trade:	$1.77M
Avg Institutional Trade (30 D):	$1M
Avg Institutional Trade (90 D):	$1.11M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.72M
Avg Closing Trade (30 D):	$.97M
Avg Closing Trade (90 D):	$.98M
Avg Closing Volume:	104.96K

News

Feb 19, 2026 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: Na

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics

Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc.

Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.57	$-1.01	$.43
Diluted EPS	$-2.57	$-1.01	$.43
Revenue	$88.24M	$3.05M	$85.09M
Gross Profit
Net Income / Loss	$-160.9M	$-68.76M	$19.4M
Operating Income / Loss	$-179.55M	$-73.62M	$14.72M
Cost of Revenue
Net Cash Flow	$-76.85M	$12.25M	$11.69M
PE Ratio